Biomarkers in the diagnosis of Alzheimer's disease: Are we ready?

Journal of Geriatric Psychiatry and Neurology

Volumn 19, Issue 3, 2006, Pages 172-179

  Sunderland, Trey ^a   Hampel, Harald ^b   Takeda, Masatoshi ^c   Putnam, Karen T ^d   Cohen, Robert M ^e  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d North Shore LIJ Health System ^*  (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Biomarkers; Cerebrospinal fluid; Diagnosis; Sensitivity and specificity

Indexed keywords

3 NITROTYROSINE; ALPHA 1 ANTICHYMOTRYPSIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C1Q; HOMOCYSTEINE; INTERLEUKIN 6 RECEPTOR; ISOPROSTANE; OXYSTEROL; TAU PROTEIN;

ALZHEIMER DISEASE; AUTOPSY; CEREBROSPINAL FLUID LEVEL; CLINICAL FEATURE; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; DAILY LIFE ACTIVITY; DEMENTIA; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; EARLY DIAGNOSIS; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MILD COGNITIVE IMPAIRMENT; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BRAIN; ELECTROENCEPHALOGRAPHY; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33746650411     PISSN: 08919887     EISSN: 15525708     Source Type: Journal    
DOI: 10.1177/0891988706291088     Document Type: Review

References (85)

1. Maltoni M, Caraceni A, Brunelli C, et al. Prognostic factors in advanced cancer patients: evidence-based clinical recommendations - a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 2005; 23:6240-6248.
2. Miller PD. Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction. Curr Osteoporos Rep 2005; 3:103-110.
3. Sunderland T, Gur RE, Arnold SE. The use of biomarkers in the elderly: current and future challenges. Biol Psychiatry 2005; 58:272-276.
4. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41:479-486.
5. Mendez MF, Mastri AR, Sung JH, Frey WH II. Clinically diagnosed Alzheimer disease: neuropathologic findings in 650 cases. Alzheimer Dis Assoc Disord 1992; 6:35-43.
6. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939-944.
7. World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva, Switzerland: World Health Organization; 1992.
8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
9. Lim A, Tsuang D, Kukull W, et al. Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series. J Am Geriatr Soc 1999; 47:564-569.
10. Newell KL, Hyman BT, Growdon JH, Hedley-Whyte ET. Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathologic diagnosis of Alzheimer disease. J Neuropathol Exp Neurol 1999; 58:1147-1155.
11. Plassman BL, Khachaturian AS, Townsend JJ, et al. Comparison of clinical and neuropathologic diagnoses of Alzheimer's disease in 3 epidemiologic samples. Alzheimer's and Dementia 2006; 2:2-11.
12. Lopez OL, Becker JT, Kaufer DI, et al. Research evaluation and prospective diagnosis of dementia with Lewy bodies. Arch Neurol 2002; 59:43-46.
13. Scinto LF, Daffner KR, Dressler D, et al. A potential noninvasive neurobiological test for Alzheimer's disease. Science 1994; 266:1051-1054.
14. Arai H, Terajima M, Miura M, et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann Neurol 1995; 38:649-652.
15. Small GW, Komo S, La Rue A, et al. Early detection of Alzheimer's disease by combining apolipoprotein E and neuroimaging. Ann N Y Acad Sci 1996; 802:70-78.
16. Jack CR Jr, Petersen RC, Xu YC, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology 1997; 49:786-794.
17. Andreasen N, Minthon L, Clarberg A, et al. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology 1999; 53:1488-1494.
18. Blennow K, Vanmechelen E, Hampel H. CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol 2001; 24:87-97.
19. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346:476-483.
20. Munzar M, Levy S, Rush R, Averback P. Clinical study of a urinary competitive ELISA for neural thread protein in Alzheimer disease. Neurol Clin Neurophysiol 2002; 2002:2-8.
21. Sunderland T, Linker G, Mirza N, et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003; 289:2094-2103.
22. Hampel H, Teipel SJ, Fuchsberger T, et al. Value of CSF beta-amyloid(1-42) and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry 2004;9:705-710.
23. Francis PT, Palmer AM, Sims NR, et al. Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment. N Engl J Med 1985; 313:7-11.
24. Mayeux R, Tang MX, Jacobs DM, et al. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann Neurol 1999; 46:412-416.
25. Mehta PD, Pirttila T, Patrick BA, Barshatzky M, Mehta SP. Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett 2001; 304:102-106.
26. Galasko D, Chang L, Motter R, et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 1998; 55:937-945.
27. Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease." The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 1998; 19:109-116.
28. Galasko D. CSF tau and Abeta42: logical biomarkers for Alzheimer's disease? Neurobiol Aging 1998; 19:117-119.
29. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003; 2:605-613.
30. Wiltfang J, Lewczuk P, Riederer P, et al. Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. World J Biol Psychiatry 2005; 6:69-84.
31. Mitchell A, Brindle N. CSF phosphorylated tau - does it constitute an accurate biological test for Alzheimer's disease? Int J Geriatr Psychiatry 2003; 18:407-411.
32. Buerger K, Zinkowski R, Teipel SJ, et al. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 2002; 59:1267-1272.
33. Hampel H, Buerger K, Zinkowski R, et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry 2004; 61:95-102.
34. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55:306-319.
35. Linker G, Mirza N, Manetti G, Meyer M, Putnam KT, Sunderland T. Fine-needle, negative-pressure lumbar puncture: a safe technique for collecting CSF. Neurology 2002; 59:2008-2009.
36. Peskind ER, Riekse R, Quinn JF, et al. Safety and acceptability of the research lumbar puncture. Alzheimer Dis Assoc Disord 2005; 19:220-225.
37. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140:566-572.
38. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56:303-308.
39. Sunderland T, Mirza N, Putnam KT, et al. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Biol Psychiatry 2004; 56:670-676.
40. Herukka SK, Helisalmi S, Hallikainen M, Tervo S, Soininen H, Pirttila T. CSF Abeta42, Tau and phosphorylated Tau, APOE varepsilon4 allele and MCI type in progressive MCI. Neurobiol Aging 2006.
41. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5:228-234.
42. de Leon MJ, DeSanti S, Zinkowski R, et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 2006; 27:394-401.
43. Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K. Cerebrospinal fluid levels of total-tau, phosphotau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurol Scand Suppl 2003; 179:47-51.
44. Mueller SG, Weiner MW, Thal LJ, et al. The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am 2005; 15:869-877, xi-xii.
45. Sager MA, Hermann B, La Rue A. Middle-aged children of persons with Alzheimer's disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer's Prevention. J Geriatr Psychiatry Neurol 2005; 18:245-249.
46. Hilsden RJ, McGregor E, Murray A, Khoja S, Bryant H. Colorectal cancer screening: practices and attitudes of gastroenterologists, internists and surgeons. Can J Surg 2005; 48:434-440.
47. O'Hare A, Fenlon H. Virtual colonoscopy in the detection of colonic polyps and neoplasms. Best Pract Res Clin Gastroenterol 2006; 20:79-92.
48. Smyth MD, Cribbs DH, Tenner AJ, et al. Decreased levels of C1q in cerebrospinal fluid of living Alzheimer patients correlate with disease state. Neurobiol Aging 1994; 15:609-614.
49. Papassotiropoulos A, Lutjohann D, Bagli M, et al. 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J Psychiatr Res 2002; 36:27-32.
50. Bretillon L, Siden A, Wahlund LO, et al. Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases. Neurosci Lett 2000; 293:87-90.
51. Morris MS, Jacques PF, Rosenberg IH, Selhub J. Hyperhomocysteinemia associated with poor recall in the third National Health and Nutrition Examination Survey. Am J Clin Nutr 2001; 73:927-933.
52. Pratico D, Clark CM, Lee VM, Trojanowski JQ, Rokach J, FitzGerald GA. Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol 2000; 48:809-812.
53. Grossman M, Farmer J, Leight S, et al. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Ann Neurol 2005; 57:721-729.
54. Licastro F, Pedrini S, Caputo L, et al. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? J Neuroimmunol 2000; 103:97-102.
55. Jobst KA, Barnetson LP, Shepstone BJ. Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and Apo E4 in medial temporal lobe dementias. Oxford Project to Investigate Memory and Aging. Int Psychogeriatr 1998; 10:271-302.
56. Nagy Z, Hindley NJ, Braak H, et al. Relationship between clinical and radiological diagnostic criteria for Alzheimer's disease and the extent of neuropathology as reflected by "stages": a prospective study. Dement Geriatr Cogn Disord 1999; 10:109-114.
57. Fox NC, Schott JM. Imaging cerebral atrophy: normal ageing to Alzheimer's disease. Lancet. 2004; 363:392-394.
58. Jack CR Jr, Dickson DW, Parisi JE, et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 2002; 58:750-757.
59. Verhoeff NP, Wilson AA, Takeshita S, et al. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry 2004; 12:584-595.
60. Bokde AL, Lopez-Bayo P, Meindl T, et al. Functional connectivity of the fusiform gyrus during a face-matching task in subjects with mild cognitive impairment. Brain 2006; 129:1113-1124.
61. Sunderland T, Wolozin B, Galasko D, et al. Longitudinal stability of CSF tau levels in Alzheimer patients. Biol Psychiatry 1999; 46:750-755.
62. Sjogren M, Vanderstichele H, Agren H, et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem 2001; 47:1776-1781.
63. Hampel H, Teipel SJ, Fuchsberger T, et al. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry 2004; 9:705-710.
64. Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995; 38:643-648.
65. Arai H. Biological markers for the clinical diagnosis of Alzheimer's disease. Tohoku J Exp Med 1996; 179:65-79.
66. Buerger K, Teipel SJ, Zinkowski R, et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 2002; 59:627-629.
67. De Jager CA, Hogervorst E, Combrinck M, Budge MM. Sensitivity and specificity of neuropsychological tests for mild cognitive impairment, vascular cognitive impairment and Alzheimer's disease. Psychol Med 2003; 33:1039-1050.
68. Nestor PJ, Scheltens P, Hodges JR. Advances in the early detection of Alzheimer's disease. Nat Med 2004; 10(suppl):S34-S41.
69. DeCarli C, Mungas D, Harvey D, et al. Memory impairment, but not cerebrovascular disease, predicts progression of MCI to dementia. Neurology 2004; 63:220-227.
70. Amieva H, Letenneur L, Dartigues JF, et al. Annual rate and predictors of conversion to dementia in subjects presenting mild cognitive impairment criteria defined according to a population-based study. Dement Geriatr Cogn Disord 2004; 18:87-93.
71. Greenwood PM, Lambert C, Sunderland T, Parasuraman R. Effects of apolipoprotein E genotype on spatial attention, working memory, and their interaction in healthy, middle-aged adults: results From the National Institute of Mental Health's BIOCARD study. Neuropsychology 2005; 19:199-211.
72. Jelic V, Johansson SE, Almkvist O, et al. Quantitative electroencephalography in mild cognitive impairment: longitudinal changes and possible prediction of Alzheimer's disease. Neurobiol Aging 2000; 21:533-540.
73. Arnaiz E, Jelic V, Almkvist O, et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport 2001; 12:851-855.
74. Visser PJ, Verhey FR, Hofman PA, Scheltens P, Jolles J. Medial temporal lobe atrophy predicts Alzheimer's disease in patients with minor cognitive impairment. J Neurol Neurosurg Psychiatry 2002; 72:491-497.
75. Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology 2003; 60:1374-1377.
76. deToledo-Morrell L, Stoub TR, Bulgakova M, et al. MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD. Neurobiol Aging 2004; 25:1197-1203.
77. Korf ES, Wahlund LO, Visser PJ, Scheltens P. Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology 2004; 63:94-100.
78. Jack CR Jr, Shiung MM, Weigand SD, et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology 2005; 65:1227-1231.
79. Arai H, Terajima M, Miura M, et al. Effect of genetic risk factors and disease progression on the cerebrospinal fluid tau levels in Alzheimer's disease. J Am Geriatr Soc 1997; 45:1228-1231.
80. Arai H, Ishiguro K, Ohno H, et al. CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp Neurol 2000; 166:201-203.
81. Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 2002; 59:1729-1734.
82. Vanderstichele H, De Meyer G, Andreasen N, et al. Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. Clin Chem 2005; 51:1650-1660.
83. Okamura N, Arai H, Maruyama M, et al. Combined analysis of CSF tau levels and [(123)I]Iodoamphetamine SPECT in mild cognitive impairment: implications for a novel predictor of Alzheimer's disease. Am J Psychiatry 2002; 159:474-476.
84. El Fakhri G, Kijewski MF, Johnson KA, et al. MRI-guided SPECT perfusion measures and volumetric MRI in prodromal Alzheimer disease. Arch Neurol 2003; 60:1066-1072.
85. Dickerson BC, Salat DH, Bates JF, et al. Medial temporal lobe function and structure in mild cognitive impairment. Ann Neurol 2004; 56:27-35.